← Back to Search

Dopamine Agonist

Pergolide for Schizotypal Personality Disorder

N/A

Waitlist Available

Led By Larry J Siever, MD

Research Sponsored by Bronx VA Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing whether the drug pergolide can improve cognitive functioning in people with schizotypal personality disorder. The trial is double-blind, meaning that neither the participants nor the researchers will know who is taking pergolide and who is taking placebo until the end of the trial. Half of the participants will receive pergolide for eight weeks while the other half will receive placebo for four weeks followed by pergolide for four weeks. The researchers will then compare the cognitive functioning of the two groups to see if there is a difference.

Who is the study for?

This trial is for medically healthy adults who meet the criteria for Schizotypal Personality Disorder or another personality disorder with cognitive impairment, but not schizophrenia-related psychotic disorders or bipolar disorder. Participants should be free from medication for two weeks and not abusing substances.Check my eligibility

What is being tested?

The study tests if a drug called pergolide can improve cognitive functions like memory and attention in patients with Schizotypal Personality Disorder. It's a randomized, double-blind crossover trial where participants get either pergolide or placebo first, then switch after four to eight weeks.See study design

What are the potential side effects?

Possible side effects of pergolide may include nausea, headache, dizziness, fatigue, dry mouth, constipation or hallucinations. Since it affects brain function, mood changes could also occur.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Performance on tests of sustained attention, episodic memory and working memory at baseline and after 2, 4, 6 and 8 weeks on the study medication

Secondary outcome measures

Hamilton Depression Rating Scale, Positive and Negative Symptom Scale and Clinical Global Impression scale at baseline and then weekly through the end of the trial

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bronx VA Medical CenterLead Sponsor

20 Previous Clinical Trials

1,286 Total Patients Enrolled

Larry J Siever, MDPrincipal InvestigatorBronx VA Medical Center/Mount Sinai School of Medicine

1 Previous Clinical Trials

20 Total Patients Enrolled

1 Trials studying Schizotypal Personality Disorder

20 Patients Enrolled for Schizotypal Personality Disorder

Media Library

Pergolide (Dopamine Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT00252044 — N/A

Schizotypal Personality Disorder Research Study Groups:

Schizotypal Personality Disorder Clinical Trial 2023: Pergolide Highlights & Side Effects. Trial Name: NCT00252044 — N/A

Pergolide (Dopamine Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00252044 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are applicants currently being accepted for this experiment?

"Checking clinicaltrials.gov, it appears that this trial is no longer recruiting—the initial post date being October 1st 2000 and the last update November 17th 2005. Despite this, there are still a plethora of other trials actively searching for participants to take part in their research."

Answered by AI

Are those aged 55 and above admissible for this medical experiment?

"Patients between 18 to 60 years old meet the requirements for this research. There are 253 trials that accept minors and 641 studies with a focus on seniors."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder

2000. "Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00252044.

All > Obsessive Compulsive Disorder > New York